Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PG 102

Next Previous
X
Search
Drug Profile

PG 102

Alternative Names: MG-12; PG-102 - ProGen; RT-114

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Progen Pharmaceuticals Inc
  • Class Antihyperglycaemics; Immunoglobulin Fc fragments; Obesity therapies; Recombinant fusion proteins
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 06 Aug 2024 Rani Therapeutics plans a phase I trial for Obesity in 2025
  • 24 Jun 2024 Rani Therapeutics collaborates with ProGen for the development of RT-114 ( an oral RaniPill® capsule containing PG-102) for Obesity
  • 21 Jun 2024 Adverse events and pharmacokinetics data from phase-Ia trial in Obesity and Type 2 diabetes mellitus (In volunteers) presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top